Company Description
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.
The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors.
It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor.
The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab.
The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025.
NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Xi-Yong Fu |
Contact Details
Address: 2440 Research Boulevard, Suite 400 Rockville, Maryland 20850 United States | |
| Phone | 240 745 6330 |
| Website | novabridge.com |
Stock Details
| Ticker Symbol | NBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001778016 |
| CUSIP Number | 44975P103 |
| ISIN Number | US44975P1030 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Xi-Yong Fu M.B.A., Ph.D. | Chief Executive Officer and Director |
| Wei Fu | Executive Chairman |
| Ming Lei | Chief Financial Officer |
| Sean Wuxiong Cao M.B.A., Ph.D. | Chief Business Development Officer and Director |
| Tyler Ehler | Senior Director of Investor Relations |
| Liwei Lin | General Counsel and Board Secretary |
| Dr. Cong Xu M.D., Ph.D. | Senior Vice President and Head of Research & Development Center of Excellence |
| Dr. Phillip Dennis M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | 6-K | Report of foreign issuer |
| Apr 7, 2026 | 6-K | Report of foreign issuer |
| Apr 7, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 18, 2026 | 144 | Filing |
| Mar 16, 2026 | 6-K | Report of foreign issuer |
| Mar 9, 2026 | 6-K | Report of foreign issuer |
| Mar 3, 2026 | 6-K | Report of foreign issuer |
| Feb 25, 2026 | 6-K | Report of foreign issuer |
| Feb 19, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | 6-K | Report of foreign issuer |